Doug Ingram, Sarepta Therapeutics CEO (Michael Nagle/Bloomberg via Getty Images)
January 27, 2025 03:36 PM ESTUpdated 03:56 PM
R&D
Pharma
FDA+

Sarep­ta shares two-year DMD study da­ta that could in­form Eu­ro­pean ap­proval de­ci­sion

Lei Lei Wu

News Reporter

Sarep­ta Ther­a­peu­tics un­veiled new re­sults from the sec­ond part of a clin­i­cal tri­al for its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py Ele­v­idys …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Swiss biotech ends Phase 2 study in Alzheimer's short­ly af­ter Lil­ly and Bio­gen did the same

Sofinno­va Part­ners rais­es €1.2B to back an­oth­er 50 to 60 life sci­ences star­tups

Bourla says Pfiz­er could trans­fer pro­duc­tion to US to side­step Trump's tar­iffs

23andMe re­jects CEO's sec­ond take-pri­vate of­fer

Pep­Gen de­lays study for Duchenne drug as it awaits safe­ty da­ta from an­oth­er tri­al

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times